Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, announces a trading update.
(more…)
TR-1: Notification of major interest in shares. (more…)
The Board has become aware of the launch of a new test by Siemens for troponin, a key biomarker used in heart attack diagnostics. (more…)
TR-1: Notification of major interest in shares. (more…)
TR-1: Notification of major interest in shares. (more…)
Unaudited interim results for the six months ended 31st December 2016. (more…)
TR-1: Notification of major interest in shares. (more…)
TR-1: Notification of major interest in shares. (more…)
Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting held earlier today, all resolutions put to shareholders were duly passed.
(more…)
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 18 November 2016 of the following transactions in its ordinary shares of 5 pence each (“Ordinary Shares”)
(more…)